Articles

ABOUT AUTHORS:
Badola Ashutosh,* Nishu Sharma
Shri Guru Ram Rai Institute of Technology & Science ( SGRRITS ),
Dehradun 248001, Uttarakhand , India
*ashutosh.badolam.pharma@gmail.com

ABSTRACT:
Controlled release local drug delivery systems offer advantages compared to systemic dosage forms for periodontitis. The objective of this research was to design and evaluate sustained release dental films containing drug in a non-biodegradable polymer for targeted delivery of the drug. The polymer ethyl cellulose was used in the formulation of dental films. The dental film was then evaluated for various parameters like thickness, folding endurance, and weight variation, and content uniformity, in vitro and in vivo study. Drug release profile of the dental film showed that the film exerted an initial burst release followed by a sustained release of the drug and the drug release was well above the minimum inhibitory concentration throughout the time of study. The release data obtained were subjected for release kinetics study. The study suggested that the non-biodegradable based dental film is a potential local drug delivery device for the treatment of periodontitis.

ABOUT AUTHOR
Kunal Roy
NSHM Group of Institutions Knowledge campus,
Department of Pharmaceutical Analysis & Quality Assurance
Kolkata-700053
kunal.roy17@gmail.com

ABSTRACT:
Counterfeit Culture is a one of the most important and dangerous crime in the world of drugs and its related products  and  explores the dangerous and sometimes deadly world of fake, fraudulent, and faux products. The pharmaceutical  industry has a has history of peddled knock-off  dosage forms, medical devices   but during the last 15 years, it has mushroomed into a global phenomenon.
The range of counterfeit goods now being produced includes pharmaceuticals. The traffic in counterfeit goods is now estimated at a staggering $350 billion representing nearly 10% of all global trade. This illicit and highly profitable criminal enterprise continues to grow unabated and has been linked to organized crime syndicates around the world.

[adsense:336x280:8701650588]

ABOUT AUTHORS:
Tripti Verma*, Keshav Vashistha, Sachin Vispute
B N College of Pharmacy,
Udaipur, Rajasthan
*triptiphsoni22@gmail.com

ABSTRACT:
The review examines the recent  trials of clopidogrel in the treatment of acute coronary syndromes, as well as current cardiac guidelines from several professional societies. As the publication of the landmark study Clopidogrel in Unstable Angina to Prevent Recurrent Events (CURE), the clinical benefit of early and intermediate-term use of combined antiplatelet agents--clopidogrel plus aspirin--in non-ST-segment elevation myocardial infarction (NSTEMI) patients became evident. Pretreatment and intermediate-term therapy with clopidogrel in NSTEMI ACS patients undergoing percutaneous coronary intervention (PCI) was further supported by the PCI-CURE trial. Recently, the results of two major trials Clopidogrel as Adjunctive Reperfusion Therapy-Thrombolysis in Myocardial Infarction 28, Clopidogrel and Metoprolol in Myocardial Infarction Trial established the pivotal role of clopidogrel in the other spectrum of ACS-STEMI. Coupled with the results from previous multicentre trials, these two studies provide a guide for the early and long-term use of clopidogrel in the whole spectrum of ACS. A review summarising the results of the recent clinical trials and a discussion on its implications for the clinical management of ACS is presented.Clopidogrel is well established in the treatment of acute coronary syndromes and is ubiquitous in cardiology practice. Landmark studies have established the importance of clopidogrel in the treatment of non-ST and ST elevation myocardial infarction and in percutaneous coronary intervention by reducing death, reinfarction, and adverse cardiac events.

ABOUT AUTHORS:
Miss Apoorva Bhatnagar¹, Dr. S. C. Mahajan^2
1Mahakal institute of pharmaceutical studies,  
²Director at Mahakal Institute of Pharmaceutical Studies,
Ujjain (m.p.)  456010
*apy1590bhtngr@gmail.com

ABOUT AUTHORS:
Mr. Gunjegaonkar shivshankar M., Mr. T.T. shelke
Dept. of Pharmacology, JSPMs Charak College of pharmacy and research,
Wagholi, Pune, Maharashtra
*gunjeshiv@gmail.com

ABOUT AUTHORS:
Neha singh*¹, Chandana Majee^2
1.M.Pharm ( Department of Pharmaceutics)
^2.Assistant Professor, Departmrnt of pharmaceutical chemistry.
Noida Institute of Engineering and Technology, Noida
*neha8april@gmail.com